Cynosure, Inc. (CYNO) Shares Sold by Frontier Capital Management Co. LLC

Frontier Capital Management Co. LLC reduced its position in Cynosure, Inc. (NASDAQ:CYNO) by 20.1% during the fourth quarter, Holdings Channel reports. The fund owned 90,835 shares of the company’s stock after selling 22,862 shares during the period. Frontier Capital Management Co. LLC’s holdings in Cynosure were worth $4,142,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in CYNO. Royal Bank of Canada increased its position in Cynosure by 52.6% in the second quarter. Royal Bank of Canada now owns 39,430 shares of the company’s stock worth $1,918,000 after buying an additional 13,594 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Cynosure by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 90,705 shares of the company’s stock worth $4,413,000 after buying an additional 1,578 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Cynosure by 1.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,125 shares of the company’s stock worth $833,000 after buying an additional 179 shares in the last quarter. Numeric Investors LLC acquired a new position in Cynosure during the second quarter worth $10,395,000. Finally, Timpani Capital Management LLC acquired a new position in Cynosure during the second quarter worth $2,889,000.

Institutional Ownership by Quarter for Cynosure (NASDAQ:CYNO)

Shares of Cynosure, Inc. (NASDAQ:CYNO) opened at 65.925 on Wednesday. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of 101.423 and a beta of 1.65. The firm has a 50-day moving average of $48.28 and a 200 day moving average of $48.42. Cynosure, Inc. has a 52-week low of $36.45 and a 52-week high of $65.95.

Cynosure (NASDAQ:CYNO) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.44 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.03. The business had revenue of $122.10 million for the quarter, compared to analyst estimates of $119.97 million. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 earnings per share. Analysts predict that Cynosure, Inc. will post $1.60 EPS for the current year.

“Cynosure, Inc. (CYNO) Shares Sold by Frontier Capital Management Co. LLC” was reported by sleekmoney and is the property of of sleekmoney. If you are viewing this news story on another domain, it was stolen and republished in violation of US & international copyright and trademark law. The legal version of this news story can be read at http://sleekmoney.com/cynosure-inc-cyno-shares-sold-by-frontier-capital-management-co-llc/1662167.html.

CYNO has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Cynosure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 19th. Brean Capital reiterated a “buy” rating on shares of Cynosure in a research note on Monday, October 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 target price (down from $62.00) on shares of Cynosure in a research note on Wednesday, October 26th. Leerink Swann reiterated an “outperform” rating and issued a $60.00 target price (down from $63.00) on shares of Cynosure in a research note on Friday, October 28th. Finally, Aegis started coverage on shares of Cynosure in a research note on Wednesday, November 2nd. They issued a “buy” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $57.88.

In other Cynosure news, Chairman Michael R. Davin sold 16,284 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total transaction of $732,780.00. Following the sale, the chairman now directly owns 4,222 shares of the company’s stock, valued at $189,990. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Douglas J. Delaney sold 7,875 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total transaction of $354,375.00. Following the sale, the vice president now directly owns 5,833 shares in the company, valued at $262,485. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Cynosure Company Profile

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

5 Day Chart for NASDAQ:CYNO

Want to see what other hedge funds are holding CYNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cynosure, Inc. (NASDAQ:CYNO).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/cynosure-inc-cyno-shares-sold-by-frontier-capital-management-co-llc/1662167.html

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *